Pertussis diagnosis in Belgium: results of the National Reference Centre for Bordetella anno 2015

H Martini, C Rodeghiero, C VAN DEN Poel, M Vincent, D Pierard, K Huygen, H Martini, C Rodeghiero, C VAN DEN Poel, M Vincent, D Pierard, K Huygen

Abstract

In 2015, the Belgian National Reference Centre for Bordetella analyzed 4110 respiratory samples by qPCR and 4877 serum samples by serology. Whereas about 50% of respiratory samples were from infants and children below the age of five, serum samples were distributed among all age categories. A total of 394 (9·6%) cases was diagnosed as positive for Bordetella pertussis by qPCR and 844 (17·3%) cases were diagnosed as acute infection by serology (anti-pertussis toxin (PT) IgG > 125 IU/ml). Another 1042 (21·4%) sera had anti-PT IgG between 55 and 125 IU/ml reflecting a vaccination or pertussis infection during the last 1-2 years. Seventy per cent of the pertussis cases diagnosed by qPRC were in infants and children younger than 14 years old, whereas the highest number of sera with anti-PT levels >125 IU/ml was in the age group of 10-14 years old. Based on the limited data of the last vaccination (reported for only 15% of the samples), recent booster vaccination in the teenager group may have contributed only minimally to these elevated anti-PT levels. The highest number of sera with anti-PT titers between 55 and 125 IU/ml was found in the age category 50-59 years old. It is clear that pertussis continues to be a problem in Belgium and that other vaccination strategies (maternal vaccination, cocoon vaccination) and ultimately better vaccines will be needed to control this highly infectious respiratory disease.

Keywords: Bordetella pertussis.

Figures

Fig. 1.
Fig. 1.
Overview of the NRC results of 2015 pertussis serodiagnosis for the different age categories (the number of samples tested is given in parentheses). The red line and figure on top of each age category indicate the median concentration calculated for each age group.

References

    1. Cherry JD. Pertussis: challenges today and for the future. Public Library of Science Pathogens 2013; 9: e1003418.
    1. Crowcroft NS, Pebody RG. Recent developments in pertussis. The Lancet 2006; 367: 1926–1936.
    1. Bart MJ, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. mBio 2014; 5: e01074.
    1. van Gent M, et al. Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012. European Journal of Clinical Microbiology and Infectious Diseases 2014; 34: 821–823.
    1. Toukouki A, et al. Whooping cough in adults, think about it! Revue Médicale de Liège 2013; 68: 177–179.
    1. Dalby T, et al. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. Journal of Medical Microbiology 2010; 59: 1029–1036.
    1. Duterme S, et al. Serodiagnosis of whooping cough in Belgium: results of the National Reference Centre for Bordetella pertussis anno 2013. Acta Clinica Belgica 2016; 71: 86–91.
    1. Niesters HG. Quantitation of viral load using real-time amplification techniques. Methods 2001; 25: 419–429.
    1. Roorda L, et al. A real-time PCR assay with improved specificity for detection and discrimination of all clinically relevant Bordetella species by the presence and distribution of three Insertion Sequence elements. BioMed Central Research Notes. 2011; 4: 11.
    1. Guthrie JL, et al. Novel duplex real-time PCR assay detects Bordetella holmesii in specimens from patients with Pertussis-like symptoms in Ontario, Canada. Journal of Clinical Microbiology 2010; 48: 1435–1437.
    1. van Doornum GJ, et al. Diagnosing herpesvirus infections by real-time amplification and rapid culture. Journal of Clinical Microbiology 2003; 41: 576–580.
    1. Mellmann H, et al. Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry in comparison to 16S rRNA gene sequencing for species identification of nonfermenting bacteria. Journal of Clinical Microbiology 2008; 46: 1946–1954.
    1. Sauer S, et al. Classification and identification of bacteria by mass spectrometry and computational analysis. Public Library of Science one 2008; 3: e2843.
    1. Guiso N, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. European Journal of Clinical Microbiology and Infectious Diseases 2011; 30: 307–312.
    1. He Q, et al. High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance. Eurosurveillance 2012; 17(32): pii=20239.
    1. Huygen K, et al. Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012. Epidemiology & Infection 2014; 142: 724–728.
    1. de Greeff SC, et al. Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. Public Library of Science one 2010; 5: e14183.
    1. Braeye T, et al. Kinkhoest. In: Peeters J, ed. Infectieziekten bij kinderen die voorkomen kunnen worden door vaccinatie. Volksgezondheid en Surveillance D/2015/2505/05, Brussels: WIV-ISP Brussels, 2015, pp. 30–40.
    1. Braeye T, et al. Capture-recapture estimators in epidemiology with applications to pertussis and pneumococcal invasive disease surveillance. Public Library of Science one 2016; 11: e0159832.
    1. Barkoff AM, Grondahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathogens and Disease 2015; 73: 1–12.
    1. Vincent M, et al. Pertussis serodiagnosis in Belgium from 1990 to 2009. Clinical and Vaccine Immunology 2011; 18: 588–594.
    1. Wendelboe AM, et al. Duration of immunity against pertussis after natural infection or vaccination. The Pediatric Infectious Disease Journal 2005; 24: S58–S61.
    1. Hoge Gezondheids Raad, Vaccinatie tegen kinkhoest. Vaccinatie van volwassenen () 2013.
    1. Maertens K, et al. Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, Belgium. Vaccine 2016; 34: 5785–5791.
    1. Maertens K, et al. Pertussis vaccination during pregnancy in Belgium: follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. Vaccine 2016; 34: 3613–3619.
    1. Caboré RN, et al. Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium. Virulence 2017; 1–10. PMID: 28277900.
    1. Brummelman J, et al. Roads to the development of improved pertussis vaccines paved by immunology. Pathogens and Disease 2015; 73: ftv067.
    1. Carbonetti NH, et al. Highlights of the 11th International Bordetella symposium: from basic biology to vaccine development. Clinical and Vaccine Immunology 2016; 23: 842–850.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren